RA treatment showdown: low activity vs. remission

NCT ID NCT06046950

Ongoing Disease control Sponsor: Sint Maartenskliniek Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares two treatment strategies for rheumatoid arthritis (RA): aiming for low disease activity versus aiming for remission. 340 adults with RA who are starting or already on disease-modifying drugs will be randomly assigned to one of these targets. The goal is to see which approach leads to better control of joint damage and symptoms over 18 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Treatment strategy (treat-to-target with DAS28CRP-LDA or SDAI-remission)
What this could lead to: If successful, this study could show which treatment target (low disease activity or remission) is more effective and cost-effective for managing rheumatoid arthritis.
What could go wrong: This is a strategy trial, not testing a new drug. Results may not apply to all patients, and the more stringent remission target may be harder to achieve or cause more side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

Sint Maartenskliniek

Ubbergen, 6574 NA, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.